Most Read Articles
Natalia Reoutova, 02 Sep 2020

Combination immunotherapy with nivolumab (1 mg/kg) and high-dose ipilimumab (3 mg/kg), given every 3 weeks (nivo1+ipi3 Q3W) for four cycles, followed by flat-dose nivolumab (240 mg) maintenance every 2 weeks (Q2W), achieved greater efficacy vs two high-dose nivolumab (3 mg/kg) and ipilimumab (1 mg/kg) regimens (nivo3+ipi1) in patients with advanced hepatocellular carcinoma (HCC) and in Asian patients, in particular, according to a subanalysis of the phase I/II CheckMate 040 trial presented at the virtual World Congress on Gastrointestinal Cancer (WCGC) 2020.

Stephen Padilla, 03 Sep 2020
Real-world systemic sequential therapy with regorafenib confers survival benefits in patients with advanced hepatocellular carcinoma (HCC) who failed first-line sorafenib, consistent with previous clinical trial, according to a study in Korea.
2 days ago
A recent study has found no significant impact of 5α-reductase inhibitors on Gleason grading, with no difference in mortality seen among users and nonusers in each Gleason group.
12 Jun 2020
Drawing from experience as a key investigator in landmark clinical trials (including PALOMA, MONALEESA and MONARCH), and his clinical experience with CDK4/6 inhibitors, Dr Rafael Villanueva Vázquez shares his insights into the current evidence of using CDK4/6 inhibitors to treat HR+/HER2- ABC.

EV-NID1 as potential target for HCC detection and treatment

Christina Lau
08 Sep 2020
From left: Dr Judy Yam, Ms Cherlie Yeung, Dr Sze-Keong Tey

Nidogen 1-enriched extracellular vesicles (EV-NID1) have demonstrated potential as a noninvasive biomarker for early detection of hepatocellular carcinoma (HCC) and as a target for HCC treatment.

Using a mouse model of HCC, researchers from the University of Hong Kong (HKU) found that NID1 in metastatic HCC–derived EVs facilitated lung colonization of tumour cells by enhancing angiogenesis and pulmonary endothelial permeability, and by activating fibroblasts to secrete tumour necrosis factor receptor 1 (TNFR1). EV-NID1 also augmented HCC cell growth and motility. [Adv Sci 2020, doi: 10.1002/advs.202002157]

Administration of anti‐TNFR1 antibody effectively diminished lung metastasis induced by the metastatic HCC cellderived EVs in mice.

In HCC patients, serum EV‐NID1 and TNFR1 were found to be positively correlated with tumour stage, indicating their potential as noninvasive biomarkers for early detection of HCC.

“These results also suggest that blockage of the function and signalling pathways of tumour-derived EVs can be applied as a new therapeutic approach for HCC in the future,” concluded investigator Dr Judy Yam of the Department of Pathology, HKU.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Natalia Reoutova, 02 Sep 2020

Combination immunotherapy with nivolumab (1 mg/kg) and high-dose ipilimumab (3 mg/kg), given every 3 weeks (nivo1+ipi3 Q3W) for four cycles, followed by flat-dose nivolumab (240 mg) maintenance every 2 weeks (Q2W), achieved greater efficacy vs two high-dose nivolumab (3 mg/kg) and ipilimumab (1 mg/kg) regimens (nivo3+ipi1) in patients with advanced hepatocellular carcinoma (HCC) and in Asian patients, in particular, according to a subanalysis of the phase I/II CheckMate 040 trial presented at the virtual World Congress on Gastrointestinal Cancer (WCGC) 2020.

Stephen Padilla, 03 Sep 2020
Real-world systemic sequential therapy with regorafenib confers survival benefits in patients with advanced hepatocellular carcinoma (HCC) who failed first-line sorafenib, consistent with previous clinical trial, according to a study in Korea.
2 days ago
A recent study has found no significant impact of 5α-reductase inhibitors on Gleason grading, with no difference in mortality seen among users and nonusers in each Gleason group.
12 Jun 2020
Drawing from experience as a key investigator in landmark clinical trials (including PALOMA, MONALEESA and MONARCH), and his clinical experience with CDK4/6 inhibitors, Dr Rafael Villanueva Vázquez shares his insights into the current evidence of using CDK4/6 inhibitors to treat HR+/HER2- ABC.